Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1977 1
1980 3
1981 4
1982 2
1983 1
1984 5
1987 4
1988 8
1989 16
1990 20
1991 22
1992 30
1993 28
1994 33
1995 33
1996 29
1997 27
1998 35
1999 26
2000 41
2001 30
2002 26
2003 39
2004 35
2005 33
2006 39
2007 41
2008 59
2009 61
2010 82
2011 85
2012 74
2013 80
2014 103
2015 112
2016 126
2017 123
2018 126
2019 162
2020 146
2021 214
2022 198
2023 165
2024 58

Text availability

Article attribute

Article type

Publication date

Search Results

2,268 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "B-cell childhood acute lymphoblastic leukemia"
Page 1
Pediatric acute lymphoblastic leukemia.
Inaba H, Mullighan CG. Inaba H, et al. Haematologica. 2020 Nov 1;105(11):2524-2539. doi: 10.3324/haematol.2020.247031. Haematologica. 2020. PMID: 33054110 Free PMC article. Review.
The last decade has witnessed great advances in our understanding of the genetic and biological basis of childhood acute lymphoblastic leukemia (ALL), the development of experimental models to probe mechanisms and evaluate new therapies, and the develo …
The last decade has witnessed great advances in our understanding of the genetic and biological basis of childhood acute ly …
Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia.
Teachey DT, Pui CH. Teachey DT, et al. Lancet Oncol. 2019 Mar;20(3):e142-e154. doi: 10.1016/S1470-2045(19)30031-2. Lancet Oncol. 2019. PMID: 30842058 Free PMC article. Review.
Contemporary paediatric clinical trials have improved 5-year event-free survival above 85% and 5-year overall survival above 90% in B-cell acute lymphoblastic leukaemia (ALL) in many study groups, whilst outcomes for T-cell ALL are still lagging …
Contemporary paediatric clinical trials have improved 5-year event-free survival above 85% and 5-year overall survival above 90% in B …
Genetic Biomarkers and Their Clinical Implications in B-Cell Acute Lymphoblastic Leukemia in Children.
Lejman M, Chałupnik A, Chilimoniuk Z, Dobosz M. Lejman M, et al. Int J Mol Sci. 2022 Mar 2;23(5):2755. doi: 10.3390/ijms23052755. Int J Mol Sci. 2022. PMID: 35269896 Free PMC article. Review.
Acute lymphoblastic leukemia (ALL) is a heterogeneous group of hematologic malignancies characterized by abnormal proliferation of immature lymphoid cells. ...In this article, we provide an overview of the latest information on genomic alterations found in …
Acute lymphoblastic leukemia (ALL) is a heterogeneous group of hematologic malignancies characterized by abnormal proli …
Clinical diagnostics and treatment strategies for Philadelphia chromosome-like acute lymphoblastic leukemia.
Harvey RC, Tasian SK. Harvey RC, et al. Blood Adv. 2020 Jan 14;4(1):218-228. doi: 10.1182/bloodadvances.2019000163. Blood Adv. 2020. PMID: 31935290 Free PMC article. Review.
Philadelphia chromosome-like B-cell acute lymphoblastic leukemia (Ph-like ALL) accounts for 15% to 30% of B-cell acute lymphoblastic leukemia in older children, adolescents, and adults and is associated with hi …
Philadelphia chromosome-like B-cell acute lymphoblastic leukemia (Ph-like ALL) accounts for 15% to 30% of …
Pharmacotypes across the genomic landscape of pediatric acute lymphoblastic leukemia and impact on treatment response.
Lee SHR, Yang W, Gocho Y, John A, Rowland L, Smart B, Williams H, Maxwell D, Hunt J, Yang W, Crews KR, Roberts KG, Jeha S, Cheng C, Karol SE, Relling MV, Rosner GL, Inaba H, Mullighan CG, Pui CH, Evans WE, Yang JJ. Lee SHR, et al. Nat Med. 2023 Jan;29(1):170-179. doi: 10.1038/s41591-022-02112-7. Epub 2023 Jan 5. Nat Med. 2023. PMID: 36604538 Free PMC article.
Contemporary chemotherapy for childhood acute lymphoblastic leukemia (ALL) is risk-adapted based on clinical features, leukemia genomics and minimal residual disease (MRD); however, the pharmacological basis of these prognostic variables remains …
Contemporary chemotherapy for childhood acute lymphoblastic leukemia (ALL) is risk-adapted based on clinical fea …
Whole-transcriptome analysis in acute lymphoblastic leukemia: a report from the DFCI ALL Consortium Protocol 16-001.
Tran TH, Langlois S, Meloche C, Caron M, Saint-Onge P, Rouette A, Bataille AR, Jimenez-Cortes C, Sontag T, Bittencourt H, Laverdière C, Lavallée VP, Leclerc JM, Cole PD, Gennarini LM, Kahn JM, Kelly KM, Michon B, Santiago R, Stevenson KE, Welch JJG, Schroeder KM, Koch V, Cellot S, Silverman LB, Sinnett D. Tran TH, et al. Blood Adv. 2022 Feb 22;6(4):1329-1341. doi: 10.1182/bloodadvances.2021005634. Blood Adv. 2022. PMID: 34933343 Free PMC article. Clinical Trial.
The molecular hallmark of childhood acute lymphoblastic leukemia (ALL) is characterized by recurrent, prognostic genetic alterations, many of which are cryptic by conventional cytogenetics. ...Gene expression profiling enabled further molecular classif …
The molecular hallmark of childhood acute lymphoblastic leukemia (ALL) is characterized by recurrent, prognostic …
Optimal approach to T-cell ALL.
O'Dwyer KM. O'Dwyer KM. Hematology Am Soc Hematol Educ Program. 2022 Dec 9;2022(1):197-205. doi: 10.1182/hematology.2022000337C. Hematology Am Soc Hematol Educ Program. 2022. PMID: 36485091 Free PMC article. Review.
T-lineage acute lymphoblastic leukemia (T-ALL) is curable for most children and adolescent and young adult patients with contemporary frontline chemotherapy regimens. ...Current T-ALL salvage chemotherapy regimens are minimally effective, and unlike in B …
T-lineage acute lymphoblastic leukemia (T-ALL) is curable for most children and adolescent and young adult patients wit …
Whole genome sequencing provides comprehensive genetic testing in childhood B-cell acute lymphoblastic leukaemia.
Ryan SL, Peden JF, Kingsbury Z, Schwab CJ, James T, Polonen P, Mijuskovic M, Becq J, Yim R, Cranston RE, Hedges DJ, Roberts KG, Mullighan CG, Vora A, Russell LJ, Bain R, Moorman AV, Bentley DR, Harrison CJ, Ross MT. Ryan SL, et al. Leukemia. 2023 Mar;37(3):518-528. doi: 10.1038/s41375-022-01806-8. Epub 2023 Jan 19. Leukemia. 2023. PMID: 36658389 Free PMC article.
Childhood B-cell acute lymphoblastic leukaemia (B-ALL) is characterised by recurrent genetic abnormalities that drive risk-directed treatment strategies. ...Whole genome sequencing (WGS) has the potential to improve genetic testing, but requires …
Childhood B-cell acute lymphoblastic leukaemia (B-ALL) is characterised by recurrent genetic abnormalitie …
Lymphoblastic lymphoma.
Cortelazzo S, Ponzoni M, Ferreri AJ, Hoelzer D. Cortelazzo S, et al. Crit Rev Oncol Hematol. 2011 Sep;79(3):330-43. doi: 10.1016/j.critrevonc.2010.12.003. Epub 2011 Jan 26. Crit Rev Oncol Hematol. 2011. PMID: 21273093 Review.
Although histological features are usually sufficient to distinguish lymphoblastic from mature B- or T-cell neoplasms, a differential diagnosis with blastoid variant of mantle cell lymphoma, Burkitt lymphoma or myeloid leukemia may arise in some cases. …
Although histological features are usually sufficient to distinguish lymphoblastic from mature B- or T-cell neoplasms, a diffe …
The Clinicogenomic Landscape of Induction Failure in Childhood and Young Adult T-Cell Acute Lymphoblastic Leukemia.
O'Connor D, Demeulemeester J, Conde L, Kirkwood A, Fung K, Papaleonidopoulou F, Bloye G, Farah N, Rahman S, Hancock J, Bateman C, Inglott S, Mee J, Herrero J, Van Loo P, Moorman AV, Vora A, Mansour MR. O'Connor D, et al. J Clin Oncol. 2023 Jul 1;41(19):3545-3556. doi: 10.1200/JCO.22.02734. Epub 2023 Apr 25. J Clin Oncol. 2023. PMID: 37098241 Free PMC article.
PURPOSE: Failure to respond to induction chemotherapy portends a poor outcome in childhood acute lymphoblastic leukemia (ALL) and is more frequent in T-cell ALL (T-ALL) than B-cell ALL. ...Despite increased use of nelarabine-based …
PURPOSE: Failure to respond to induction chemotherapy portends a poor outcome in childhood acute lymphoblastic leuke …
2,268 results